Minase Research Institute, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan.
Bioorg Med Chem. 2011 Sep 15;19(18):5432-45. doi: 10.1016/j.bmc.2011.07.055. Epub 2011 Jul 31.
To identify an orally active corticotropin-releasing factor 1 receptor antagonist, a series of 6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives were designed, synthesized and evaluated. An in vitro study followed by in vivo and pharmacokinetic studies of these heterotricyclic compounds led us to the discovery of an orally active CRF1 receptor antagonist. The results of a structure-activity relationship study are presented.
为了鉴定一种具有口服活性的促肾上腺皮质激素释放因子 1 型受体拮抗剂,设计、合成并评估了一系列 6,7-二氢-5H-环戊并[d]吡唑并[1,5-a]嘧啶及其衍生物。通过对这些杂三环化合物的体外研究,以及体内和药代动力学研究,我们发现了一种具有口服活性的 CRF1 受体拮抗剂。本文呈现了构效关系研究的结果。